Evidence map›Paper›PMID 41134695›Full record

ArticleEuropean thyroid journal2025

Reply to the letter by Dr Karlsson 'Rationale behind the European Thyroid Association 2024 Guideline to treat the Allan-Herndon-Dudley syndrome with tiratricol?'

Luca Persani, Patrice Rodien, Carla Moran, W Edward Visser, Stefan Groeneweg, Robin Peeters, Samuel Refetoff, Mark Gurnell, Paolo Beck-Peccoz, Krishna Chatterjee

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in European thyroid journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luca PersaniDepartment of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milano, Italy.ORCID https://orcid.org/0000-0003-2068-9581
Patrice RodienService d'Endocrinologie-Diabétologie-Nutrition, Centre de référence des maladies rares de la Thyroïde et des récepteurs hormonaux, CHU d'Angers, Angers, France.ORCID https://orcid.org/0000-0002-7785-5627
Carla MoranInstitute of Metabolic Science, University of Cambridge, Cambridge, UK.
W Edward VisserDepartment of Internal Medicine and Rotterdam Thyroid Center, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-5248-863X
Stefan GroenewegDepartment of Internal Medicine and Rotterdam Thyroid Center, Erasmus University Medical Center, Rotterdam, The Netherlands.
Robin PeetersDepartment of Internal Medicine and Rotterdam Thyroid Center, Erasmus University Medical Center, Rotterdam, The Netherlands.
Samuel RefetoffDepartments of Medicine and Paediatrics and Committee on Genetics, The University of Chicago, Chicago, Illinois, USA.
Mark GurnellInstitute of Metabolic Science, University of Cambridge, Cambridge, UK.
Paolo Beck-PeccozDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Italy.
Krishna ChatterjeeInstitute of Metabolic Science, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0002-2654-8854

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical practice guidelinedeiodinasediagnosis and managementimpaired sensitivity to thyroid hormonesresistance to thyroid hormoneselenoproteinthyroid hormone receptorthyroid hormone transporter

Identifiers

PMID41134695
PMCPMC12555026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.